$750.00$14,100.00

Rapid Alpha-Pseudoviruses for Respiratory Syncytial Virus

In stock
Reporter Gene Firefly Luciferase
Size and Price 5 x 200 µL ~20 wells/96 well plate, 10 x 200 µL ~40 wells/96 well plate, 25 x 200 µL ~100 wells/96 well plate, 50 x 200 µL ~200 wells/96 well plate, 100 x 200 µL ~400 wells/96 well plate, 5 x 100 µL (Concentrated Only)
N/A

Product Description

Product Description

Rapid Alpha-Pseudovirus for Respiratory Syncytial Virus

Built-to-order alpha-pseudovirus for RSV with the attachment Glycoprotein (G), Fusion protein (F), Nucleoprotein (N), Matrix protein (M), and the Short Hydrophobic protein (SH).

Applications
  • RSV pseudovirus transduction of target cells for viral entry and functional studies
  • Rapid Anti-RSV drug screening
  • Rapid Anti-RSV neutralizing antibody screening

A novel rapid hybrid alpha-pseudovirus for Respiratory Syncytial Virus (Ha-RSV) and other Pneumoviridae viruses are now available at Virongy. Ha-RSV particles are pseudoviruses assembled from the structural proteins of the Respiratory Syncytial Virus: Glycoprotein (G), fusion protein (F), Nucleoprotein (N), Matrix protein (M), and a short hydrophobic (SH) protein. These particles encapsulate an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-amplifying RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. Furthermore, we assist our customers in constructing Ha-RSV pseudoviruses at any scale.

For inquiries, please reach out to us via email: info@virongy.com

To enhance your pseudovirus entry, inquire about receiving a complimentary sample of our proprietary Infectin, which significantly enhances productive viral infection in various host cells, thereby boosting the viral infection rate by 3- to 20-fold.

Background:

RSV (Respiratory Syncytial Virus), an Orthopneumovirus, is a spherical enveloped virus with a diameter of approximately 150 nm. Its genome is a linear, negative-stranded RNA spanning about 15 kb and encoding 11 proteins. RSV attaches to host cell receptors via the HN glycoprotein, fuses with the plasma membrane, and releases its ribonucleocapsid into the cytoplasm. The viral RNA-dependent RNA polymerase initiates transcription by binding to the encapsidated genome at the leader region, sequentially transcribing viral genes by recognizing start and stop signals. During transcription, viral mRNAs receive caps and polyadenylation by the L protein in the cytoplasm. Replication begins as sufficient nucleoprotein encapsulates neo-synthesized antigenomes and genomes. Finally, the ribonucleocapsid interacts with the matrix protein under the plasma membrane, leading to budding via the ESCRT complex and virion release.

Discovered in 1956, RSV is a major cause of respiratory tract infections, particularly in infants, young children, and the elderly. Transmission occurs primarily via respiratory droplets and fomites. In healthy individuals, RSV manifests as mild cold-like symptoms, while in vulnerable populations, it can lead to severe lower respiratory tract infections, including bronchiolitis and pneumonia. Although no specific antiviral treatment exists, supportive care is crucial. Ongoing research aims to develop vaccines and antiviral interventions to mitigate RSV’s impact.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899062/